1. Home
  2. MDWD vs QBTS Comparison

MDWD vs QBTS Comparison

Compare MDWD & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • QBTS
  • Stock Information
  • Founded
  • MDWD 2000
  • QBTS 1999
  • Country
  • MDWD Israel
  • QBTS United States
  • Employees
  • MDWD N/A
  • QBTS N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • QBTS Retail: Computer Software & Peripheral Equipment
  • Sector
  • MDWD Health Care
  • QBTS Technology
  • Exchange
  • MDWD Nasdaq
  • QBTS Nasdaq
  • Market Cap
  • MDWD 230.6M
  • QBTS 5.0B
  • IPO Year
  • MDWD 2014
  • QBTS N/A
  • Fundamental
  • Price
  • MDWD $19.12
  • QBTS $16.00
  • Analyst Decision
  • MDWD Strong Buy
  • QBTS Strong Buy
  • Analyst Count
  • MDWD 2
  • QBTS 7
  • Target Price
  • MDWD $35.00
  • QBTS $13.57
  • AVG Volume (30 Days)
  • MDWD 48.5K
  • QBTS 53.6M
  • Earning Date
  • MDWD 08-13-2025
  • QBTS 08-07-2025
  • Dividend Yield
  • MDWD N/A
  • QBTS N/A
  • EPS Growth
  • MDWD N/A
  • QBTS N/A
  • EPS
  • MDWD N/A
  • QBTS N/A
  • Revenue
  • MDWD $19,213,000.00
  • QBTS $21,363,000.00
  • Revenue This Year
  • MDWD $20.80
  • QBTS $181.95
  • Revenue Next Year
  • MDWD $26.92
  • QBTS $55.49
  • P/E Ratio
  • MDWD N/A
  • QBTS N/A
  • Revenue Growth
  • MDWD N/A
  • QBTS 121.61
  • 52 Week Low
  • MDWD $14.14
  • QBTS $0.75
  • 52 Week High
  • MDWD $24.00
  • QBTS $19.77
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 40.24
  • QBTS 56.67
  • Support Level
  • MDWD $19.11
  • QBTS $13.57
  • Resistance Level
  • MDWD $19.87
  • QBTS $15.44
  • Average True Range (ATR)
  • MDWD 0.63
  • QBTS 0.99
  • MACD
  • MDWD -0.17
  • QBTS -0.27
  • Stochastic Oscillator
  • MDWD 25.31
  • QBTS 70.84

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About QBTS D-Wave Quantum Inc.

D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.

Share on Social Networks: